Research And Development Tenders

Maintenance Materials for K-Mo Business Institutes

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Elbasvir + Grazoprevir, (Obo) Atc J05ap54 for the Period March 1St, 2025 - February 28Th, 2027

Dynamic Purchase System for Continuous and Repeated Purchases of Infusion Techniques and Accessories

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Erythropoietin Exclusively Epoetin Alfa, (Obo) Atc B03xa01 for the Period March 1St, 2025 - February 28Th, 2027

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Nitisinone, (Obo) Atc A16ax04 for the Period March 1St, 2025 - February 28Th, 2027

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Ustekinumab, (Obg) Atc L04ac05 for the Period March 1St, 2025 - February 28Th, 2027

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Atovaquone, (Obg) Atc P01ax06 for the Period March 1St, 2025 - February 28Th, 2027

Medicine Discount Contracts in Accordance with Section 130A Paragraph 8 Sgb V as Part of Open House Procedures

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Bempedoic Acid + Ezetimibe, (Obo) Atc C10ba10 for the Period March 1St, 2025 - February 28Th, 2027

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Pegfilgrastim, (Obo) Atc L03aa13 for the Period March 1St, 2025 - February 28Th, 2026 (Plus Extension Option 1X12 Months)